Zhao Yan's new drug hit the limit
Zhao Yan New Drug (603127) hit the limit on November 4th, 2024. It closed at 18.66 yuan, up 10.02%. The limit was up, the turnover rate was 2.08%, the turnover was 131,200 lots, and the turnover was 241 million yuan. On that day, the main net capital flow was 102 million yuan, accounting for 42.46% of the total turnover, the net outflows of hot money were 43.2413 million yuan, accounting for 17.96% of the total turnover, and the net outflows of individual investors were 58.9723 million yuan, accounting for 24.5% of the total turnover.
Zhao Yan's New Drug News
On November 5, the data of Shanghai and Shanghai Finance showed that Zhaoyan New Drug had obtained 60 million yuan of financing purchase, ranking 406th in the two cities. The repayment amount of the day's financing was 41 million yuan, and the net purchase was 18.6629 million yuan. In the last three trading days (1st-5th), Zhao Yan New Drug was bought with 18 million yuan, 6 million yuan and 60 million yuan respectively. In terms of margin lending, 2,100 shares were sold on the same day, and 20,400 shares were bought. As of November 5, Southbound Capital held 41.1067 million shares of Zhaoyan New Drug, with a market value of 400 million Hong Kong dollars, a decrease of 3.5965 million Hong Kong dollars compared with the previous trading day, and the number of shares held accounted for 34.53% of the issued shares. As of the close on the 5th, Zhao Yan New Drug fell 0.51% on the day, closing at 9.72 Hong Kong dollars.
How's Zhao Yan's new drug stock?
Zhao Yan's stock performance was affected by many factors. According to the recent situation of margin trading, on November 6, Zhaoyan New Drug obtained 57 million yuan of margin trading purchase, but the repayment amount of margin trading on that day was 68 million yuan, and the net sales amount was 10.9155 million yuan. In the last three trading days, the margin trading purchase amount was 6 million yuan, 60 million yuan and 57 million yuan respectively. On the day of margin trading, 10,300 shares were sold, and 8,100 shares were sold. In terms of performance, the previous decline in performance had a great impact on the stock price. For example, in the first half of 2024, the net profit of the parent company declined by a large margin. The fluctuation of the monkey price caused the performance to explode. The net profit fell by more than 70% year-on-year. The net loss of the monkey price alone exceeded 170 million yuan, which caused the stock price to face pressure. For example, on July 17,2023, the stock price fell to the limit, and the stock price fell by two-thirds in the recent year. Judging from the stock trend, the current trend is slow. The C wave has not yet fallen, and it may test 15.92 yuan. On November 7, the price of its A shares was 19.55 yuan, up 2.09% from the previous day. On that day, the price was 19.79 yuan, the opening price was 18.80 yuan, and the low price was 18.66 yuan. The trading volume was 170,600 lots, the total market value was 14.652 billion yuan, the turnover rate was 2.71%, the turnover was 329 million yuan, and the price-earnings TLM loss; On November 6, the closing price of its H shares was 9.74 Hong Kong dollars. As of November 6, South Capital held 42.842 million shares of Zhaoyan New Drug, with a market value of 417 million Hong Kong dollars, an increase of 17.7245 million Hong Kong dollars compared with the previous trading day. The number of shares held accounted for 35.99% of the issued shares. On November 6, AH premium reached 113.41%, ranking 52nd in AH share premium rate. Overall, Zhao Yan's stock was affected by many factors such as performance and market trends.
What's the target price of Zhao Yan's new drug?
In the past 90 days, the average target price of Zhaoyan New Drug was 18.55 yuan. Guotai Junan issued a research report on November 3 to maintain its overweight rating, with a target price of 19.6 yuan. Citic Security gave a target price of 23 yuan on October 8. Zhaoyan New Drug received the attention of two research reports from stockholders in the past month, with an average target price of 21.30 yuan. There was also a view that the first target was about 28 yuan.
Zhao Yan's new medicine fell by the limit today
According to the current reference information, today (November 7,2024), Zhao Yan New Drug did not have any limit information. It rose by 0.21% on the day and closed at 9.74 Hong Kong dollars.
Zhaoyan New Drug 10.02% Limit
On November 4, 2024, Zhaoyan New Drug (603127) closed at 18.66 yuan, up 10.02%, reaching the limit. At 9:39 on the same day, Zhao Yan New Drug hit the limit and did not open. As of the closing date, the fund was 60.0905 million yuan, accounting for 0.51% of its current market value. In terms of capital flow on that day, the main net capital flow was 102 million yuan, accounting for 42.46% of the total turnover, the net outflows of hot money funds were 43.2413 million yuan, accounting for 17.96% of the total turnover, and the net outflows of individual investors were 58.9723 million yuan, accounting for 24.5% of the total turnover. Zhao Yan's new drug was a hot stock for gene editing, stem cells, and CAR-T therapy concepts. On that day, these concepts rose by 2.87%, 2.55%, and 2.08%, respectively. The medical service industry was also in a rising state, led by Sanbo Brain.
Zhao Liying's new drama is a hit online
Zhao Liying's new drama," Here Comes the Hottest Hit ", could be watched online.
Yang Mi, Zhao Liying's new drama hit the model
Yang Mi and Zhao Liying's appearances in the new drama were indeed similar. In some photos and reports, it could be seen that both of them had chosen similar ancient costumes and even had the same hairstyle and clothing style. It was not uncommon for actors to clash with each other in style in the entertainment industry. When actors chose a character's style, they might be influenced by the needs of the character and market trends. Although their appearances were similar, each person's performance style and character setting were unique, so their performance in the drama might be different. As for the results of this drama, there was no relevant information at the moment.
Rongtai shares hit the limit limit
Rongtai shares (605133) hit the daily limit on April 16. The stock price fell by 9.98%, and the current price was 19.94 yuan. Rongtai shares belonged to the auto parts industry, and the leading stock was N Hongxin. The stock was a hot concept stock for new energy vehicles and auto parts. According to the capital flow data, the main capital had flowed in on April 15th. However, the search results did not provide any information on the specific reason why Rongtai shares hit the limit.
Fengzhu textile hit the limit limit
Phoenix Bamboo (600493) hit the daily limit on multiple days of trading. Specifically, the stock hit its daily limit on January 22, and the price fell by 10.01%. Similarly, the stock hit its daily limit on February 5 and April 27, falling 10.07% and 9.93% respectively. The textile manufacturing industry of Phoenix Bamboo was currently in a state of decline. The leading stocks were Huafu Fashion, Yunzhong Ma and Huali Group. Phoenix Bamboo was a textile and clothing company that was involved in the concept of anti-bacteria fabrics and dyeing.
Hit by Yan Xiaoyi's arrow
Fan Xian had been hit by Yan Xiaoyi's arrow, but he was not injured. Fan Xian used his Tyrannical zhenqi to protect himself, so that the arrow did not harm him. In addition, Fan Xian had deliberately left behind rags and arrowheads to make Yan Xiaoyi believe that he had been shot and to eliminate the suspicion that he was an assassin. Fan Xian's zhenqi had also improved as a result, causing his power to rise to the ninth-level, becoming a grandmaster-level ace. Thus, Fan Xian was shot but not injured.